Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
790.65
+3.73 (0.47%)
At close: Jul 10, 2025, 4:00 PM
790.40
-0.25 (-0.03%)
After-hours: Jul 10, 2025, 7:59 PM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $12.73B in the quarter ending March 31, 2025, with 45.17% growth. This brings the company's revenue in the last twelve months to $49.00B, up 36.38% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$49.00B
Revenue Growth
+36.38%
P/S Ratio
14.52
Revenue / Employee
$1,042,621
Employees
47,000
Market Cap
709.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
LLY News
- 6 hours ago - Eli Lilly Comes Out As ADA Winner - Seeking Alpha
- 1 day ago - Zepbound Powers Eli Lilly's Upbeat Q2 Outlook - Benzinga
- 1 day ago - US FDA approves gradual dosing for Lilly Alzheimer's drug - Reuters
- 1 day ago - FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease - PRNewsWire
- 2 days ago - Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon' - CNBC
- 3 days ago - Demand for obesity drugs shoots up in India as Lilly, Novo jostle for market share - Reuters
- 3 days ago - Eli Lilly's 3-step strategy to dominate the $95 billion obesity market - Business Insider
- 6 days ago - Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. - Barrons